To test this hypothesis, IL-9 secreted in media conditioned by CLL cells treated in vitro for 48 h with the BTK inhibitor Ibrutinib was quantified by ELISA. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.